Faculty profile

Ali Salahpour

Back to faculty

ProfessorDepartment of Pharmacology and ToxicologyUniversity of Toronto

Ali Salahpour

Professor

Department of Pharmacology and Toxicology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Scholar

Supervision signals

Professors usually supervise graduate students in their department's programs.
10 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (7 CIHR, 1 NSERC), most recently in 2024.
Supervised 5 trainees who won CIHR awards, most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Dopamine Transporter Deficiency Syndrome Cannabinoids Cannabis,L-Dopa Induced Dyskinesia,L-Dopa,Motor Behaviour Parkinson'S Disease,Bupropion

Latest papers

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.
EMBO molecular medicine · 2026 · senior author
Neurodevelopmental disorder‐causing GRIN1 Y647S variant alters red blood cell physiology in mice
Physiological Reports · 2026
Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction.
Nature · 2025

All 33 publications

Latest funding

Fiber Photometry in a Dopamine Deficient DAT-KO Model of Parkinson’s Disease
CIHR · 2026 · Supervisor
$9,000
Modulation of the Cannabinoid system to enhance L-DOPA responsiveness and prevent L-DOPA Induced Dyskinesia.
CIHR · 2024 · Nominated PI
$1,005,976
Modulation of the Cannabinoid system to enhance L-DOPA responsiveness and prevent L-DOPA Induced Dyskinesia.
CIHR · 2024 · Nominated PI
$50,000

All 17 grants and awards

33 publications.

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.

Russo EE, Rezayof A, Wallace C, Williams EQ, Beerepoot P, Milenkovic M, Novalen M, Blundell A, Lipina TV, Locke J, Christian R, Finnie PSB, Edgar LJ, Tyndale RF, Watkins-Chow D, Ramsey AJ, Jones SR, Salahpour A

EMBO molecular medicine2026Senior author

DOI: 10.1038/s44321-026-00381-0 PMID: 41699258

Neurodevelopmental disorder‐causing GRIN1 Y647S variant alters red blood cell physiology in mice

Okafor SC, Horsfall W, Finnie PSB, Holicka C, Wen T, Khatir B, Loriamini M, Salahpour A, Golovin K, Branch DR

Physiological Reports2026

DOI: 10.14814/phy2.70759

Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction.

Oosterlaken M, Rogliardo A, Lipina T, Lafon PA, Tsitokana ME, Keck M, Cahuzac H, Prieu-Sérandon P, Diem S, Derieux C, Camberlin C, Lafont C, Meyer D, Chames P, Vandermoere F, Marin P, Prézeau L, Servent D, Salahpour A, Ramsey AJ, Bécamel C, Pin JP, Kniazeff J, Rondard P

Nature2025

DOI: 10.1038/s41586-025-09265-8 PMID: 40702184

Combination of Haloperidol With UNC9994, β-arrestin-Biased Analog of Aripiprazole, Ameliorates Schizophrenia-Related Phenotypes Induced by NMDAR Deficit in Mice.

Lipina TV, Giang H, Thacker JS, Wetsel WC, Caron MG, Beaulieu JM, Salahpour A, Ramsey AJ

The international journal of neuropsychopharmacology2024

DOI: 10.1093/ijnp/pyae060 PMID: 39612588

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.

Wang X, Marmouzi I, Finnie PSB, Bucher ML, Yan Y, Williams EQ, Støve SI, Lipina TV, Ramsey AJ, Miller GW, Salahpour A

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024Senior author

DOI: 10.1038/s41386-024-01914-2 PMID: 39060436

Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification.

Yang A, Chidiac R, Russo E, Steenland H, Pauli Q, Bonin R, Blazer LL, Adams JJ, Sidhu SS, Goeva A, Salahpour A, Angers S

Development (Cambridge, England)2024

DOI: 10.1242/dev.202545 PMID: 38358799

Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.

Mielnik CA, Li CK, Ramsey AJ, Salahpour A, Burnham WM, Ross RA

Cannabis and cannabinoid research2024

DOI: 10.1089/can.2022.0125 PMID: 36251462

Evaluation and Validation of Commercially Available Dopamine Transporter Antibodies.

Russo EE, Zovko LE, Nazari R, Steenland H, Ramsey AJ, Salahpour A

eNeuro2023Senior author

DOI: 10.1523/eneuro.0341-22.2023 PMID: 37142435

Abnormal sensory perception masks behavioral performance of Grin1 knockdown mice.

Lipina T, Men X, Blundell M, Salahpour A, Ramsey AJ

Genes, brain, and behavior2022

DOI: 10.1111/gbb.12825 PMID: 35705513

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.

Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, Ramsey AJ, Mash DC, Olson DE, Blough B, Salahpour A

Frontiers in cellular neuroscience2022Senior author

DOI: 10.3389/fncel.2022.832536 PMID: 35614973

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Ali Salahpour

Research

Latest papers

Latest funding

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.

Neurodevelopmental disorder‐causing GRIN1 Y647S variant alters red blood cell physiology in mice

Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction.

Combination of Haloperidol With UNC9994, β-arrestin-Biased Analog of Aripiprazole, Ameliorates Schizophrenia-Related Phenotypes Induced by NMDAR Deficit in Mice.

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.

Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification.

Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.

Evaluation and Validation of Commercially Available Dopamine Transporter Antibodies.

Abnormal sensory perception masks behavioral performance of Grin1 knockdown mice.

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.

Fiber Photometry in a Dopamine Deficient DAT-KO Model of Parkinson’s Disease

Modulation of the Cannabinoid system to enhance L-DOPA responsiveness and prevent L-DOPA Induced Dyskinesia.

Modulation of the Cannabinoid system to enhance L-DOPA responsiveness and prevent L-DOPA Induced Dyskinesia.

The Development of Novel Neuroactive Compounds to Combat Parasitic Nematodes

Development and Characterization of Novel CB1 Allosteric Modulators

Unveiling the role of glutamate in dopamine transporter deficiency syndrome

Molecular and cellular mechanisms of dopamine transporter pharmacological chaperones.

Neurochemical and behavioural characterisation of a novel Dopamine Transporter Deficiency Syndrome mouse model.

Drug Metabolism in the Brain: CYP2D and Neuroprotection

Frequent collaborators

Stephane Angers

Amy Ramsey

Robert Bonin

Shreejoy Tripathy

Matthieu Schapira

Graham Scott

Ali Salahpour

Research

Latest papers

Latest funding

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.

Neurodevelopmental disorder‐causing GRIN1 Y647S variant alters red blood cell physiology in mice

Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction.

Combination of Haloperidol With UNC9994, &#x3b2;-arrestin-Biased Analog of Aripiprazole, Ameliorates Schizophrenia-Related Phenotypes Induced by NMDAR Deficit in Mice.

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.

Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification.

Cannabidiol, but Not &#x394;9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.

Evaluation and Validation of Commercially Available Dopamine Transporter Antibodies.

Abnormal sensory perception masks behavioral performance of Grin1 knockdown mice.

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.

Frequent collaborators

Stephane Angers

Amy Ramsey

Robert Bonin

Shreejoy Tripathy

Matthieu Schapira

Graham Scott

Combination of Haloperidol With UNC9994, β-arrestin-Biased Analog of Aripiprazole, Ameliorates Schizophrenia-Related Phenotypes Induced by NMDAR Deficit in Mice.

Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.